SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

N/AActive Not RecruitingNCT05408936

University of Patras80 enrolled

Overview

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

SGLT2 inhibitorDRUG

Patients receive an SGLT2 inhibitor as part of theirn routine care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * type 2 diabetes * Hba1C\>7% on their current treatment * introduction of SGLT2 inhibitor as part of their routine care Exclusion Criteria: * eGFR\<60 ml/min

Locations (1)

University Hospital of Patras

Pátrai, Greece

Outcomes

Primary Outcomes

Hemoglobin

Time frame: 0-1-3 months

Erythropoetin

Time frame: 0-1-3 months

NT-proBNP

Time frame: 0-1-3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.